




Instance: composition-en-31b0725ade6496816df8ac216511de2c
InstanceOf: CompositionUvEpi
Title: "Composition for tukysa Package Leaflet"
Description:  "Composition for tukysa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp96a2770893faca379fee3152cb2ad6db)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tukysa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What TUKYSA is and what it is used for </li>
<li>What you need to know before you take TUKYSA </li>
<li>How to take TUKYSA </li>
<li>Possible side effects </li>
<li>How to store TUKYSA </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tukysa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tukysa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What TUKYSA is 
TUKYSA is a medicine for breast cancer. It contains the active substance tucatinib and it belongs to a 
group of medicines called protein kinase inhibitors which prevent the growth of some types of cancer 
cells in the body. </p>
<p>What TUKYSA is used for 
TUKYSA is used for adults who have breast cancer which:</p>
<ul>
<li>has a receptor (target) on the cancer cells called human epidermal growth factor receptor 2 
(HER2-positive breast cancer) </li>
<li>has spread beyond the original tumour or to other organs such as the brain or cannot be 
removed by surgery  </li>
<li>has previously been treated with certain other breast cancer treatments  </li>
</ul>
<p>TUKYSA is taken with two other cancer medicines, trastuzumab and capecitabine. Separate patient 
information leaflets are available for these medicines. Ask your doctor to tell you about them. </p>
<p>How TUKYSA works 
TUKYSA works by blocking the HER2 receptors on cancer cells. HER2 produces signals that can 
help the cancer to grow, and blocking it may slow or stop cancer cells from growing or may kill them 
altogether. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tukysa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tukysa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take TUKYSA 
* if you are allergic to tucatinib or any of the other ingredients of this medicine (listed in section 6) </p>
<p>Warnings and precautions 
* Talk to your doctor before taking TUKYSA if you have liver problems. During your treatment, 
your doctor will run tests to check that your liver is working properly. </p>
<ul>
<li>
<p>TUKYSA can cause severe diarrhoea. Talk to your doctor right away at the first sign of 
diarrhoea (loose stool) and if your diarrhoea persists with nausea and/or vomiting.  </p>
</li>
<li>
<p>TUKYSA may cause harm to an unborn baby when taken by a pregnant woman. Talk to your 
doctor before you take TUKYSA if you think you may be pregnant or are planning to have a 
baby. See section on  Pregnancy and breast-feeding  below. </p>
</li>
</ul>
<p>Children and adolescents 
TUKYSA should not be used in children under the age of 18 years. The safety of TUKYSA and how 
effective it is has not been studied in this age group. </p>
<p>Other medicines and TUKYSA<br />
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Some medicines may affect the way TUKYSA works or TUKYSA may affect the way they work. 
These medicines include some medicines in the following groups: </p>
<ul>
<li>St John s wort   a herbal product used to treat depression </li>
<li>itraconazole, ketoconazole, voriconazole, posaconazole   used to treat fungal infections </li>
<li>rifampicin   used to treat bacterial infections  </li>
<li>darunavir, saquinavir, tipranavir   used to treat HIV </li>
<li>phenytoin, carbamazepine   used to treat epilepsy or a painful condition of the face called 
trigeminal neuralgia or to control serious mood disorder when other medicines do not work </li>
<li>buspirone  used to treat certain mental health problems </li>
<li>sirolimus, tacrolimus   used to control your body s immune response after a transplant </li>
<li>digoxin   used to treat heart problems </li>
<li>lomitapide, lovastatin   used to treat abnormal cholesterol levels </li>
<li>alfentanil   used for pain relief </li>
<li>avanafil, vardenafil   used to treat erectile dysfunction  </li>
<li>darifenacin   used to treat urinary incontinence </li>
<li>midazolam, triazolam  used to treat seizures, anxiety disorders, panic, agitation, and insomnia </li>
<li>repaglinide   used to treat type 2 diabetes </li>
<li>ebastine   an antihistamine used to treat seasonal and perennial allergic rhinitis and 
rhino-conjunctivitis. </li>
<li>everolimus, ibrutinib   used to treat certain cancers </li>
<li>naloxegol   used to treat to treat constipation </li>
</ul>
<p>Pregnancy and breast-feeding 
TUKYSA may cause harmful effects to an unborn baby when taken by a pregnant woman. Your doctor 
will do a pregnancy test before you start taking TUKYSA. 
* If you are pregnant, think you may be pregnant or are planning to have a baby, ask your 
doctor for advice before taking this medicine. The doctor will weigh the potential benefit to you 
against the risk to the unborn baby.<br />
<em> Use a reliable method of contraception to avoid becoming pregnant while you are taking 
TUKYSA and for at least 1 week after the last dose.<br />
</em> If you are male and have a female sexual partner who can become pregnant, use a reliable 
method of contraception to avoid pregnancy while you are taking TUKYSA and for at least 
1 week after the last dose.<br />
* If you become pregnant during treatment with TUKYSA, tell your doctor. The doctor will 
assess the potential benefit to you of continuing this medicine and the risk to the unborn baby. </p>
<p>It is not known whether TUKYSA passes into breast milk. 
* If you are breast feeding or planning to breast feed, ask your doctor for advice before taking 
this medicine. You should not breastfeed during treatment with TUKYSA and for at least 1 week 
after the last dose. Talk to your doctor about the best way to feed your baby during treatment. </p>
<p>Ask your doctor or pharmacist for advice before taking TUKYSA if you have any questions. </p>
<p>Driving and using machines 
TUKYSA is not expected to affect your ability to drive or operate machines. However, you are 
responsible for deciding whether you can drive a motor vehicle or perform other tasks that require 
increased concentration.  </p>
<p>TUKYSA contains sodium and potassium 
This medicine contains 55.3 mg sodium (main component of cooking/table salt) in each 300 mg dose. 
This is equivalent to 2.75% of the recommended maximum daily dietary intake of sodium for an adult. </p>
<p>This medicine contains 60.6 mg potassium per 300 mg dose. To be taken into consideration by patients 
with reduced kidney function or patients on a controlled potassium diet.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tukysa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tukysa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or 
pharmacist if you are not sure.  </p>
<p>Dosage 
The recommended dose is 300 mg (two 150 mg tablets) by mouth twice a day. </p>
<p>Your doctor may change your dose of TUKYSA if you experience certain side effects. To allow for a 
lower dose, your doctor may prescribe 50 mg tablets. </p>
<p>Method of administration 
TUKYSA can be taken with food or between meals.<br />
* Swallow the tablets whole, one after the other. 
* Take each dose about 12 hours apart at the same times every day. 
* Do not chew or crush the tablet. 
* Do not take an additional dose if you vomit after taking TUKYSA but continue with the next 
scheduled dose. </p>
<p>If you take more TUKYSA than you should<br />
Talk to a doctor or pharmacist straight away. If possible, show them the pack. </p>
<p>If you forget to take TUKYSA<br />
Do not take a double dose to make up for a forgotten dose. Just take the next dose at the scheduled 
time. </p>
<p>If you stop taking TUKYSA<br />
TUKYSA is for long-term treatment and you should take it continuously. Do not stop taking TUKYSA 
without talking to your doctor. </p>
<p>While you are taking TUKYSA<br />
* Depending on the side effects you have, your doctor may recommend lowering your dose or 
temporarily stopping your treatment. 
* Your doctor will also check your liver function during treatment with TUKYSA. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The 
following side effects may occur with this medicine. </p>
<p>Very common (may affect more than 1 in 10 people): 
* diarrhoea; 
* feeling sick (nausea); 
* being sick (vomiting); 
* mouth sores, inflammation of the mouth, mouth ulcers; 
* liver problems, which may cause itching, yellowing of eyes and skin, dark urine and pain or 
discomfort in the upper right area of the stomach; 
* rash; 
* joint pain; 
* weight loss; 
* nosebleed </p>
<p>Tell your doctor or pharmacist if you notice any side effects. </p>
<p>Reporting of side effects 
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any 
possible side effects not listed in this leaflet. You can also report side effects directly via the national 
reporting system listed in Appendix V. 
By reporting side effects, you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tukysa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tukysa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and the carton. The expiry 
date refers to the last day of that month. </p>
<p>This medicinal product does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What TUKYSA contains<br />
The active substance is tucatinib. Each film-coated tablet contains either 50 mg or 150 mg 
tucatinib. 
The other ingredients are:<br />
* Tablet core - copovidone, crospovidone, sodium chloride, potassium chloride, sodium hydrogen 
carbonate, silica, colloidal anhydrous, magnesium stearate, microcrystalline cellulose (see 
section 2  TUKYSA contains sodium and potassium ). 
* Film-coating   poly (vinyl alcohol), titanium dioxide, macrogol, talc, yellow iron oxide. </p>
<p>What TUKYSA looks like and contents of the pack<br />
TUKYSA 50 mg film-coated tablets (tablets) are round, yellow and debossed with  TUC  on one side 
and  50  on the reverse side.<br />
TUKYSA 150 mg film-coated tablets (tablets) are oval shaped, yellow, and debossed with  TUC  on 
one side and  150  on the reverse side.  </p>
<p>TUKYSA is supplied in aluminium foil blisters. Each pack contains:<br />
TUKYSA 50 mg film-coated tablets<br />
<em> 88 tablets (11 blisters of 8 tablets each).<br />
TUKYSA 150 mg film-coated tablets<br />
</em> 84 tablets (21 blisters of 4 tablets each). </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Seagen B.V. 
Evert van de Beekstraat 1-1118CL Schiphol<br />
The Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Seagen B.V. (Nederland/Pays-Bas/Niederlande) 
T l/Tel: +32 7848 27 Lietuva 
Swixx Biopharma UAB<br />
Tel: +370 5 236 9<br />
Swixx Biopharma EOOD <br />
Te .: +359 2 4942 Luxembourg/Luxemburg 
Seagen B.V. (Pays-Bas/Niederlande) 
T l/Tel: +352 27 867  esk  republika 
Swixx Biopharma s.r.o.<br />
Tel: +420 242 434 Magyarorsz g 
Swixx Biopharma Kft. 
Tel.: +36 1 9206 Danmark 
Seagen Denmark ApS 
Tlf: +45 89 88 83 Malta 
Genesis Pharma (Cyprus) Ltd ( ipru/Cyprus) 
Tel: +357 22 765Deutschland 
Seagen Germany GmbH 
Tel: +49 893 803 6Nederland 
Seagen B.V. 
Tel: +31 202 419Eesti 
Swixx Biopharma O <br />
Tel: +372 640 1Norge 
Seagen B.V. (Nederland) 
Tlf: +45 89 88 83 <br />
     . <br />
 : +30 210 87 71  sterreich 
Seagen B.V. (Niederlande) 
Tel: (+43) 720 778Espa a 
Seagen Spain S.L.U. 
Tel: (+34) 919 011 Polska 
Swixx Biopharma Sp.z o.o. 
Tel.: +48 22 460 07 France 
Seagen France SAS 
T l: +33 184 88 80 Portugal 
Seagen B.V. (Pa ses Baixos) 
Tel: (+351) 211 451 Hrvatska 
Swixx Biopharma d.o.o.<br />
Tel: +385 1 2078 Rom nia 
Swixx Biopharma S.R.L. 
Tel: +40 371 530 Ireland 
Seagen B.V. (Netherlands) 
Tel: +353 1903 9Slovenija 
Swixx Biopharma d.o.o.<br />
Tel: +386 1 2355  sland 
Seagen B.V. (Holland) 
S mi: +354 539 0Slovensk  republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 20833 Italia 
Seagen Italy S.r.l. 
Tel: (+39) 02 82952Suomi/Finland 
Seagen B.V. (Alankomaat/Nederl nderna) 
Puh/Tel: +358 753 252 <br />
Genesis Pharma (Cyprus) Ltd<br />
 : +357 22 765Sverige 
Seagen B.V. (Nederl nderna) 
Tel: (+46) 108 885 Latvija 
Swixx Biopharma SIA<br />
Tel: +371 6 6164 United Kingdom (Northern Ireland) 
Seagen B.V. (Netherlands) 
Tel: +44 330 818 0This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-31b0725ade6496816df8ac216511de2c
InstanceOf: CompositionUvEpi
Title: "Composition for tukysa Package Leaflet"
Description:  "Composition for tukysa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp96a2770893faca379fee3152cb2ad6db)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tukysa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage TUKYSA 
3. Sådan skal du tage TUKYSA 
4. Bivirkninger 
5. Opbevaring af TUKYSA 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tukysa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tukysa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Virkning af TUKYSA 
TUKYSA er et lægemiddel mod brystkræft. Det indeholder det aktive stof tucatinib, og det tilhører en 
gruppe lægemidler, der hedder proteinkinasehæmmere, som forhindrer væksten af nogle typer 
kræftceller i kroppen. </p>
<p>Anvendelse af TUKYSA 
TUKYSA anvendes til voksne, der har brystkræft, som:</p>
<ul>
<li>har en receptor (et mål) på kræftcellerne, der kaldes human epidermal vækstfaktorreceptor 2 
(HER2-positiv brystkræft) </li>
<li>har spredt sig ud over den oprindelige tumor eller til andre organer, som hjernen, eller som ikke 
kan fjernes kirurgisk </li>
<li>tidligere er blevet behandlet med visse andre brystkræftbehandlinger </li>
</ul>
<p>TUKYSA tages sammen med to andre kræft-lægemidler, trastuzumab og capecitabin. Separate 
indlægssedler fås for disse lægemidler. Bed din læge om at fortælle dig om dem. </p>
<p>Sådan fungerer TUKYSA 
TUKYSA fungerer ved at blokere HER2-receptorerne på kræftceller. HER2 danner signaler, som kan 
hjælpe kræften med at vokse, og hvis det blokeres kan det forsinke kræftcellerne eller få dem til at 
ophøre med at vokse eller måske slå dem helt ihjel. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tukysa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tukysa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke TUKYSA </p>
<ul>
<li>hvis du er allergisk over for tucatinib eller et af de øvrige indholdsstoffer i TUKYSA (angivet i 
afsnit 6). </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<ul>
<li>
<p>Kontakt lægen, før du tager TUKYSA, hvis du har leverproblemer. Under din behandling vil 
lægen foretage undersøgelser for at kontrollere, at din lever fungerer korrekt. </p>
</li>
<li>
<p>TUKYSA kan medføre alvorlig diarré. Kontakt straks lægen ved første tegn på diarré (løs 
afføring), og hvis din diarré vedvarer med kvalme og/eller opkastning. </p>
</li>
<li>
<p>TUKYSA kan medføre skader på det ufødte barn, hvis det tages af gravide kvinder. Kontakt 
lægen, før du tager TUKYSA, hvis du tror, at du er gravid, eller hvis du planlægger at blive 
gravid. Se afsnittet om "Graviditet og amning" nedenfor. </p>
</li>
</ul>
<p>Børn og unge 
TUKYSA bør ikke anvendes af børn under 18 år. TUKYSA's sikkerhed og virkning er ikke blevet 
undersøgt i denne aldersgruppe. </p>
<p>Brug af andre lægemidler sammen med TUKYSA 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget 
andre lægemidler eller planlægger at tage andre lægemidler. </p>
<p>Nogle lægemidler kan påvirke måden TUKYSA virker på eller TUKYSA kan påvirke den måde, de 
virker på. Disse lægemidler omfatter nogle i de følgende grupper: </p>
<ul>
<li>
<p>Prikbladet perikum - et naturlægemiddel, der bruges til at behandle depression </p>
</li>
<li>
<p>itraconazol, ketoconazol, voriconazol, posaconazol - bruges til at behandle svampeinfektioner </p>
</li>
<li>
<p>rifampicin - bruges til at behandle bakterieinfektioner, </p>
</li>
<li>
<p>darunavir, saquinavir, tipranavir - anvendes til behandling af HIV </p>
</li>
<li>
<p>phenytoin, carbamazepin - anvendes til at behandle epilepsi eller en smertefuld sygdom i 
ansigtet, der kaldes trigeminusneuralgi, eller til at kontrollere alvorlige humørsvingninger, når 
andre lægemidler ikke virker </p>
</li>
<li>
<p>buspiron - anvendes til at behandle visse mentale forstyrrelser </p>
</li>
<li>
<p>sirolimus, tacrolimus - anvendes til at kontrollere kroppens immunforsvar efter en transplantation </p>
</li>
<li>
<p>digoxin - anvendes til behandling af hjerteproblemer </p>
</li>
<li>
<p>lomitapid, lovastatin - anvendes til behandling af anormale kolesterolniveauer </p>
</li>
<li>
<p>alfentanil - anvendes til smertelindring </p>
</li>
<li>
<p>avanafil, vardenafil - anvendes til behandling af erektil dysfunktion (impotens) </p>
</li>
<li>
<p>darifenacin - anvendes til behandling af urininkontinens </p>
</li>
<li>
<p>midazolam, triazolam - anvendes til behandling af kramper, angstlidelser, panikangst, uro og 
søvnløshed </p>
</li>
<li>
<p>repaglinid - anvendes til behandling af type 2-diabetes </p>
</li>
<li>
<p>ebastin - et antihistamin, der anvendes til behandling af sæsonbetinget- og 
helårshøfeber </p>
</li>
<li>
<p>everolimus, ibrutinib - anvendes til behandling af visse kræfttyper </p>
</li>
<li>
<p>naloxegol - anvendes til behandling af forstoppelse </p>
</li>
</ul>
<p>Graviditet og amning 
TUKYSA kan medføre skadelige virkninger på det ufødte barn, hvis det tages af gravide kvinder. Din 
læge vil tage en graviditetstest, inden du begynder at tage TUKYSA. </p>
<ul>
<li>
<p>Hvis du er gravid, har mistanke om, at du er gravid eller planlægger at blive gravid, skal du 
spørge din læge til råds, før du tager dette lægemiddel. Lægen vil afveje den mulige fordel for dig 
mod risikoen for det ufødte barn. </p>
</li>
<li>
<p>Anvend sikker prævention for at undgå at blive gravid, mens du tager TUKYSA og mindst 1 
uge efter den sidste dosis. </p>
</li>
<li>
<p>Hvis du er mand og har en kvindelig partner, der kan blive gravid, skal du anvende 
sikker prævention for at undgå graviditet, mens du tager TUKYSA i mindst 1 uge efter den 
sidste dosis. </p>
</li>
<li>
<p>Hvis du bliver gravid under behandling med TUKYSA, skal du kontakte lægen. Lægen vil 
vurdere den mulige fordel for dig ved at fortsætte dette lægemiddel og vurdere risikoen for det 
ufødte barn. </p>
</li>
</ul>
<p>Det vides ikke, om TUKYSA udskilles i modermælk. </p>
<ul>
<li>Hvis du ammer eller planlægger at amme, skal du spørge din læge til råds, før du tager dette 
lægemiddel. Du bør ikke amme under behandling med TUKYSA og i mindst 1 uge efter den sidste 
dosis. Tal med lægen om, hvordan du bedst giver dit barn mad under behandlingen. </li>
</ul>
<p>Spørg din læge eller apotekspersonalet til råds, før du tager TUKYSA, hvis du har spørgsmål. </p>
<p>Trafik- og arbejdssikkerhed 
TUKYSA forventes ikke at påvirke evnen til at føre motorkøretøj eller betjene maskiner. Du har 
imidlertid selv ansvaret for at beslutte, om du kan føre et motorkøretøj eller udføre andre opgaver, der 
kræver øget koncentration. </p>
<p>TUKYSA indeholder natrium og kalium 
Dette lægemiddel indeholder 55,3 mg natrium (hovedkomponent af madlavnings-/bordsalt) pr. 300 mg 
dosis. Dette svarer til 2,75 % af den anbefalede maksimale daglige indtagelse af natrium for en voksen. </p>
<p>Dette lægemiddel indeholder 60,6 mg kalium pr. 300 mg dosis. Hvis du har nedsat nyrefunktion og/eller 
får kaliumfattig diæt, skal du tage hensyn hertil. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tukysa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tukysa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Dosering 
Den anbefalede dosis er 300 mg (to 150 mg tabletter) gennem munden to gange dagligt. </p>
<p>Din læge kan ændre din TUKYSA-dosis, hvis du får visse bivirkninger. For at kunne muliggøre en 
lavere dosis, kan din læge ordinere tabletter på 50 mg. </p>
<p>Administration 
TUKYSA kan tages med mad eller mellem måltider. </p>
<ul>
<li>
<p>Synk tabletterne hele, en ad gangen. </p>
</li>
<li>
<p>Tag hver dosis med ca. 12 timers mellemrum på samme tid hver dag. </p>
</li>
<li>
<p>Tabletterne må ikke tygges eller knuses. </p>
</li>
<li>
<p>Du må ikke tage en supplerende dosis, hvis du kaster op efter, at du har taget TUKYSA, men 
fortsætte med den næste, planlagte dosis. </p>
</li>
</ul>
<p>Hvis du har taget for meget TUKYSA 
Tal med en læge eller apotekspersonalet med det samme. Vis dem lægemiddelpakningen, hvis det er 
muligt. </p>
<p>Hvis du har glemt at tage TUKYSA 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. Tag blot den næste dosis på det 
planlagte tidspunkt. </p>
<p>Hvis du holder op med at tage TUKYSA 
TUKYSA er til langvarig behandling, og du skal tage det kontinuerligt. Du må ikke holde op med at 
tage TUKYSA uden at tale med din læge. </p>
<p>Mens du tager TUKYSA </p>
<ul>
<li>
<p>Afhængigt af de bivirkninger, du har, kan din læge anbefale at reducere dosen eller midlertidigt 
standse din behandling. </p>
</li>
<li>
<p>Lægen vil også tjekke din leverfunktion under behandlingen med TUKYSA. </p>
</li>
</ul>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. Der 
kan ses følgende bivirkninger med dette lægemiddel. </p>
<p>Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer): </p>
<ul>
<li>
<p>diarré </p>
</li>
<li>
<p>kvalme </p>
</li>
<li>
<p>opkastning </p>
</li>
<li>
<p>mundsår, betændelse i munden </p>
</li>
<li>
<p>leverproblemer, som kan forårsage kløe, gulfarvning af øjne og hud, mørk urin og smerter eller 
ubehag i mavens øvre, højre område </p>
</li>
<li>
<p>udslæt </p>
</li>
<li>
<p>ledsmerter </p>
</li>
<li>
<p>vægttab </p>
</li>
<li>
<p>næseblod. </p>
</li>
</ul>
<p>Fortæl lægen eller apotekspersonalet, hvis du bemærker bivirkninger. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. </p>
<p>Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af 
dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tukysa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tukysa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Tag ikke lægemidlet efter den udløbsdato, der står på blisteren og æsken. Udløbsdatoen er den sidste dag 
i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du ikke 
smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>TUKYSA indeholder: 
Aktivt stof: tucatinib. Hver filmovertrukket tablet indeholder enten 50 mg eller 150 mg tucatinib. 
Øvrige indholdsstoffer: </p>
<ul>
<li>
<p>Tabletkerne: copovidon, crospovidon, natriumchlorid, kaliumchlorid, natriumhydrogencarbonat, 
silica; kolloid vandfri, magnesiumstearat, mikrokrystallinsk cellulose (se afsnit 2 "TUKYSA 
indeholder natrium og kalium"). </p>
</li>
<li>
<p>Filmovertræk: polyvinylalkohol, titandioxid, macrogol, talcum, gul jernoxid. </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser for TUKYSA 
TUKYSA 50 mg filmovertrukne tabletter (tabletter) er runde, gule og præget med "TUC" på den ene side 
og "50" på den anden side. 
TUKYSA 150 mg filmovertrukne tabletter (tabletter) er ovale, gule og præget med "TUC" på den ene 
side og "150" på den anden side. </p>
<p>TUKYSA leveres i blistere af aluminiumfolie. Hver pakning indeholder: 
TUKYSA 50 mg filmovertrukne tabletter </p>
<ul>
<li>
<p>88 tabletter (11 blistere med 8 tabletter i hver). 
TUKYSA 150 mg filmovertrukne tabletter </p>
</li>
<li>
<p>84 tabletter (21 blistere med 4 tabletter i hver). </p>
</li>
</ul>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Seagen B.V. 
Evert van de Beekstraat 1-1118CL Schiphol 
Holland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Seagen B.V. (Nederland/Pays-Bas/Niederlande) 
Tél/Tel: +32 7848 27 Lietuva 
Swixx Biopharma UAB<br />
Tel: +370 5 236 9България 
Swixx Biopharma EOOD <br />
Teл.: +359 2 4942 Luxembourg/Luxemburg 
Seagen B.V. (Pays-Bas/Niederlande) 
Tél/Tel: +352 27 867 Česká republika 
Swixx Biopharma s.r.o.<br />
Tel: +420 242 434 Magyarország 
Swixx Biopharma Kft. 
Tel.: +36 1 9206 Danmark 
Seagen Denmark ApS 
Tlf.: +45 89 88 83 Malta 
Genesis Pharma (Cyprus) Ltd (Ċipru/Cyprus) 
Tel: +357 22 765Deutschland 
Seagen Germany GmbH 
Tel: +49 893 803 6Nederland 
Seagen B.V. 
Tel: +31 202 419Eesti 
Swixx Biopharma OÜ<br />
Tel: +372 640 1Norge 
Seagen B.V. (Nederland) 
Tlf: +45 89 88 83 Ελλάδα 
ΓΕΝΕΣΙΣ ΦΑΡΜΑ Α.Ε<br />
Τηλ: +30 210 87 71 Österreich 
Seagen B.V. (Niederlande) 
Tel: (+43) 720 778España 
Pfizer, S.L. 
Tel: +34 91 490 99 Polska 
Swixx Biopharma Sp.z o.o. 
Tel.: +48 22 460 07 France 
Seagen France SAS 
Tél: +33 184 88 80 Portugal 
Seagen B.V. (Países Baixos) 
Tel: (+351) 211 451 Hrvatska 
Swixx Biopharma d.o.o.<br />
Tel: +385 1 2078 România 
Swixx Biopharma S.R.L. 
Tel: +40 371 530 Ireland 
Seagen B.V. (Netherlands) 
Tel: +353 1903 9Slovenija 
Swixx Biopharma d.o.o.<br />
Tel: +386 1 2355 Ísland 
Seagen B.V. (Holland) 
Sími: +354 539 0Slovenská republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 20833 Italia 
Seagen Italy S.r.l. 
Tel: (+39) 02 82952Suomi/Finland 
Seagen B.V. (Alankomaat/Nederländerna) 
Puh/Tel: +358 753 252 Κύπρος 
Genesis Pharma (Cyprus) Ltd<br />
Τηλ: +357 22 765Sverige 
Seagen B.V. (Nederländerna) 
Tel: (+46) 108 885 Latvija 
Swixx Biopharma SIA<br />
Tel: +371 6 6164 United Kingdom (Northern Ireland) 
Seagen B.V. (Netherlands) 
Tel: +44 330 818 0 
Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside:<br />
http://www.ema.europa.eu </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-31b0725ade6496816df8ac216511de2c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tukysa Package Leaflet for language en"
Description: "ePI document Bundle for tukysa Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-31b0725ade6496816df8ac216511de2c"
* entry[0].resource = composition-en-31b0725ade6496816df8ac216511de2c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp31b0725ade6496816df8ac216511de2c"
* entry[=].resource = mp31b0725ade6496816df8ac216511de2c
                            
                    
Instance: bundlepackageleaflet-da-31b0725ade6496816df8ac216511de2c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tukysa Package Leaflet for language da"
Description: "ePI document Bundle for tukysa Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-31b0725ade6496816df8ac216511de2c"
* entry[0].resource = composition-da-31b0725ade6496816df8ac216511de2c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp31b0725ade6496816df8ac216511de2c"
* entry[=].resource = mp31b0725ade6496816df8ac216511de2c
                            
                    



Instance: mp31b0725ade6496816df8ac216511de2c
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product TUKYSA 50 mg film-coated tablets"
Description: "TUKYSA 50 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "TUKYSA 50 mg film-coated tablets: EU/1/20/1526/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "TUKYSA 50 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 31b0725ade6496816df8ac216511de2cListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "tukysa"

* status = #current
* mode = #working

* title = "List of all ePIs associated with tukysa"

* subject = Reference(mp96a2770893faca379fee3152cb2ad6db)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#tukysa "tukysa"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-31b0725ade6496816df8ac216511de2c) // tukysa en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-31b0725ade6496816df8ac216511de2c) // tukysa da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-31b0725ade6496816df8ac216511de2c
InstanceOf: List

* insert 31b0725ade6496816df8ac216511de2cListRuleset
    